

(12) PATENT APPLICATION PUBLICATION

(21) Application No.202311026435 A

(19) INDIA

(22) Date of filing of Application :10/04/2023

(43) Publication Date : 19/05/2023

(54) Title of the invention : Pharmaceutical Composition Comprising Synta66 For Attenuating Seizure Development

<p>(51) International classification :A61B 050000, F16B 350400, F16L 150000, G02B 062600, G03F 013200</p> <p>(86) International Application No :PCT// Filing Date :01/01/1900</p> <p>(87) International Publication No : NA</p> <p>(61) Patent of Addition to Application Number :NA Filing Date :NA</p> <p>(62) Divisional to Application Number :NA Filing Date :NA</p>	<p>(71)Name of Applicant : 1)Chitkara University Address of Applicant :Chitkara University, Chandigarh-Patiala National Highway, Village Jhansla, Rajpura, Punjab - 140401, India Rajpura -----</p> <p>2)Chitkara Innovation Incubator Foundation Name of Applicant : NA Address of Applicant : NA</p> <p>(72)Name of Inventor : 1)Dr. Thakur Gurjeet Singh Address of Applicant :Chitkara College of Pharmacy, Chitkara University, Chandigarh-Patiala National Highway, Village Jhansla, Rajpura, Punjab - 140401, India Rajpura ----- ---</p> <p>2)Dr. Shareen Singh Address of Applicant :Chitkara College of Pharmacy, Chitkara University, Chandigarh-Patiala National Highway, Village Jhansla, Rajpura, Punjab - 140401, India Rajpura ----- ---</p>
---	--

(57) Abstract :

ABSTRACT PHARMACEUTICAL COMPOSITION COMPRISING SYNTA66 FOR ATTENUATING SEIZURE DEVELOPMENT The present disclosure relates generally to pharmaceutical compositions. More specifically, the disclosure is directed to a pharmaceutical composition for attenuating development of seizure comprising of Syntaa 66 (N-(2',5'-dimethoxy-[1, -biphenyl]-4-yl)-3-fluoroisonicotinamide) and one or more pharmaceutically acceptable excipients. Further, it provides a method for preparing the injectable formulations compositions comprising Syntaa 66 (N-(2',5'-dimethoxy-[1, -biphenyl]-4-yl)-3-fluoroisonicotinamide) and one or more pharmaceutically acceptable excipients. Figure 1

No. of Pages : 28 No. of Claims : 10